Abstract:Background Tumor-associated macrophages (TAMs) play key roles in the development of many malignant solid tumors including breast cancer. They are educated in the tumor microenvironment (TME) to promote tumor growth, metastasis, and therapy resistance. However, the phenotype of TAMs is elusive and how to regulate them for therapeutic purpose remains unclear; therefore, TAM-targeting therapies have not yet achieved clinical success. The purposes of this study were to examine the role of transcription factor EB (TFEB) in regulating TAM gene expression and function and to determine if TFEB activation can halt breast tumor development. Methods Microarrays were used to analyze the gene expression profile of macrophages (MΦs) in the context of breast cancer and to examine the impact of TFEB overexpression. Cell culture studies were performed to define the mechanisms by which TFEB affects MΦ gene expression and function. Mouse studies were carried out to investigate the impact of MΦ TFEB deficiency or activation on breast tumor growth. Human cancer genome data were analyzed to reveal the prognostic value of TFEB and its regulated genes. Results TAM-mimic MΦs display a unique gene expression profile, including significant reduction in TFEB expression. TFEB overexpression favorably modulates TAM gene expression through multiple signaling pathways. Specifically, TFEB upregulates suppressor of cytokine signaling 3 (SOCS3) and peroxisome proliferator-activated receptor γ (PPARγ) expression and autophagy/lysosome activities, inhibits NLRP3 (NLR Family Pyrin Domain Containing 3) inflammasome and hypoxia-inducible factor (HIF)-1α mediated hypoxia response, and thereby suppresses an array of effector molecules in TAMs including arginase 1, interleukin (IL)-10, IL-1β, IL-6 and prostaglandin E2. MΦ-specific TFEB deficiency promotes, while activation of TFEB using the natural disaccharide trehalose halts, breast tumor development by modulating TAMs. Analysis of human patient genome database reveals that expression levels of TFEB, SOCS3 and PPARγ are positive prognostic markers, while HIF-1α is a negative prognostic marker of breast cancer. Conclusions Our study identifies TFEB as a master regulator of TAMs in breast cancer. TFEB controls TAM gene expression and function through multiple autophagy/lysosome-dependent and independent pathways. Therefore, pharmacological activation of TFEB would be a promising therapeutic approach to improve the efficacy of existing treatment including immune therapies for breast cancer by favorably modulating TAM function and the TME.

EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1α pathway

EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1 alpha pathway

Abstract P4-08-23: ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer

E2F1 Renders Prostate Cancer Cell Resistant to ICAM-1 Mediated Antitumor Immunity by NF-κB Modulation.

E2F1 Transactivates IQGAP3 and Promotes Proliferation of Hepatocellular Carcinoma Cells Through IQGAP3-mediated PKC-alpha Activation.

ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer

CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation

ETHE1 Accelerates Triple-Negative Breast Cancer Metastasis by Activating GCN2/eIF2α/ATF4 Signaling

ETHE1 Accelerates Triple-Negative Breast Cancer Metastasis by Activating GCN2/eIF2/ATF4 Signaling

Targeting Hypoxia and HIF1α in Triple-Negative Breast Cancer: New Insights from Gene Expression Profiling and Implications for Therapy

E1AF promotes breast cancer cell cycle progression via upregulation of Cyclin D3 transcription

TFEB is a master regulator of tumor-associated macrophages in breast cancer

Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy

LncRNA LINC00649 promotes the growth and metastasis of triple-negative breast cancer by maintaining the stability of HIF-1α through the NF90/NF45 complex

Targeting TAF1 with BAY-299 Induces Antitumor Immunity in Triple-Negative Breast Cancer.

EHD1 Promotes Breast Cancer Metastasis Through Upregulating HIF2a Expression Via Activating Mtor Pathway

Suppression of breast cancer progression by FBXL16 via oxygen-independent regulation of HIF1α stability

UBE3B promotes breast cancer progression by antagonizing HIF-2α degradation

YTHDC1‐dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple‐negative breast cancer

EZH2 regulates expression of FOXC1 by mediating H3K27me3 in breast cancers

Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1